GPR35; GPBAR1; DRD4; | |
NPSR1; CXCR1; | |
ALPI; ALPL; RECQL; PLA2G1B; TDP1; APOBEC3G; PKM; PIK3CA; PIK3CG; PIK3CB; PIK3R1; GLO1; HPGD; PGD; MPO; AKR1B1; HSD17B2; HSD17B10; ALOX15; AKR1B10; NQO2; ALDH1A1; ALOX12; GFER; NOX4; USP2; PYGL; APEX1; POLB; CD38; | |
PTPN1; CDC25B; PTPN2; | |
ACHE; GAA; | |
HDAC3; | |
BCL2; | |
TOP2A; | |
NEK6; AKT1; MET; BCR; GSK3B; CSNK2A1; DAPK1; SYK; NEK2; AXL; FLT3; PKN1; CAMK2B; SRC; IGF1R; AURKB; INSR; CDK1; MAPK14; PIM1; NUAK1; ALK; PTK2; MYLK; KDR; | |
CA7; CA3; CA14; CA5B; CA1; CA12; CA13; CA4; CA6; CA2; CA9; CA5A; | |
NR1H4; | |
ESR1; ESR2; | |
KDM4E; | |
MAOA; ALOX5; PTGS1; PTGS2; XDH; | |
MMP13; MMP3; MMP2; MMP9; | |
BACE1; | |
STAT6; HIF1A; NFKB1; TP53; | |
ABCC1; ABCG2; | |
SLC6A2; SLCO1B3; SLCO1B1; | |
LMNA; MAPT; GMNN; THPO; HTT; RAB9A; NPC1; APP; | |
L3MBTL1; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | APOBEC3G | DNA dC->dU-editing enzyme APOBEC-3G | Q9HC16 | CHEMBL1741217 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
Enzyme_unclassified | PIK3CG | PI3-kinase p110-gamma subunit | P48736 | CHEMBL3267 |
Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Histone deacetylase | HDAC3 | Histone deacetylase 3 | O15379 | CHEMBL1829 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | BCR | Bcr/Abl fusion protein | P11274 | CHEMBL2096618 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | MAPK14 | MAP kinase p38 alpha | Q16539 | CHEMBL260 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | MYLK | Myosin light chain kinase, smooth muscle | Q15746 | CHEMBL2428 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
SLC superfamily of solute carriers | SLC6A2 | Norepinephrine transporter | P23975 | CHEMBL222 |
SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | GMNN | Geminin | O75496 | CHEMBL1293278 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0020037; heme binding | 1.228E-12 | 3.991E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, MPO, NOX4, PTGS1, PTGS2, SRC |
MF | GO:0005488; binding | GO:0005524; ATP binding | 2.163E-12 | 6.543E-10 | ABCC1, ABCG2, AKT1, ALK, AURKB, AXL, BCR, CAMK2B, CDK1, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, INSR, KDR, MAPK14, MET, MYLK, NEK2, NEK6, NUAK1, PIK3CA, PIK3CB, PIK3CG, PIM1, PKM, PKN1, PTK2, PYGL, RECQL, SRC, SYK, TOP2A, TP53 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 7.467E-12 | 1.959E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, NOX4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.043E-11 | 2.671E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.618E-11 | 6.265E-09 | ALPI, APOBEC3G, CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, GLO1, L3MBTL1, MMP13, MMP2, MMP3, MMP9, NQO2, NR1H4, PTPN1, TP53 |
MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 4.899E-11 | 1.036E-08 | AKT1, ALK, AURKB, BCR, CAMK2B, CDK1, CSNK2A1, DAPK1, GSK3B, MAPK14, MYLK, NEK2, NEK6, NUAK1, PIK3CA, PIK3CG, PIM1, PKN1, SYK |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.348E-10 | 2.552E-08 | AURKB, CA2, CA7, HIF1A, HTT, MAPK14, NEK2, NPC1, NPSR1, NR1H4, PIK3CB, PLA2G1B, PTGS2, SYK |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.358E-10 | 5.897E-08 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, XDH |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 8.468E-10 | 1.308E-07 | AURKB, BCL2, CA2, CA7, CD38, HIF1A, HTT, KDR, MAPK14, NEK2, NPC1, NPSR1, NR1H4, PIK3CB, PLA2G1B, PTGS2, SRC, SYK |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.417E-09 | 1.965E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.548E-09 | 3.363E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.769E-09 | 3.610E-07 | AXL, INSR, MET, NOX4, PIK3CA, PIK3CB, PIK3CG, PIK3R1, PTK2, SRC, THPO |
MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 3.816E-09 | 4.748E-07 | IGF1R, INSR, PIK3CA, PIK3CB, PIK3R1 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.693E-09 | 5.584E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 6.509E-09 | 7.499E-07 | CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP3A4 |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 1.506E-08 | 1.647E-06 | AXL, KDR, MAPK14, PIK3CA, PIK3CB, PIK3R1, PTK2, SRC |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.105E-08 | 2.203E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 3.519E-08 | 3.483E-06 | ALOX12, ALOX15, ALOX5, HPGD, PTGS2 |
CC | GO:0044464; cell part | GO:0005829; cytosol | 1.111E-07 | 1.008E-05 | AKR1B1, AKR1B10, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, APOBEC3G, APP, AURKB, BCL2, BCR, CA1, CA13, CA2, CA3, CA7, CAMK2B, CDC25B, CDK1, CSNK2A1, FLT3, GFER, GLO1, GMNN, GSK3B, HDAC3, HIF1A, HPGD, HTT, LMNA, MAPK14, MAPT, MYLK, NEK2, NEK6, NFKB1, NQO2, PGD, PIK3CA, PIK3CB, PIK3CG, PIK3R1, PIM1, PKM, PKN1, PLA2G1B, PTK2, PTPN1, PTPN2, PYGL, RAB9A, SRC, STAT6, SYK, TP53, XDH |
BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 2.189E-07 | 1.891E-05 | AKT1, BCL2, CYP1B1, DAPK1, GSK3B, HPGD, HTT, MAPT, MMP9, NOX4, PIK3CB, PTGS2, PTPN2, SRC, TOP2A, TP53, XDH |
BP | GO:0009987; cellular process | GO:0030168; platelet activation | 4.236E-07 | 3.454E-05 | AKT1, AXL, PIK3CA, PIK3CB, PIK3CG, PIK3R1, SRC, SYK |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 4.421E-07 | 3.592E-05 | IGF1R, INSR, KDR, PTK2, SRC, SYK |
BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 5.492E-07 | 4.381E-05 | AKT1, BCL2, CAMK2B, CDK1, CSNK2A1, GSK3B, PKN1 |
BP | GO:0032502; developmental process | GO:0001525; angiogenesis | 5.810E-07 | 4.600E-05 | CYP1B1, HIF1A, KDR, MAPK14, MMP2, PIK3CA, PIK3CB, PIK3CG, PTGS2, PTK2, SYK |
BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 6.632E-07 | 5.067E-05 | AKT1, HIF1A, INSR, NOX4, NR1H4, PIK3CA, PIK3R1, PTPN2, PYGL |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 6.747E-07 | 5.137E-05 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 7.460E-07 | 5.582E-05 | AKT1, BCL2, MAPT, PTPN1, TP53 |
BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 1.608E-06 | 1.126E-04 | AXL, BCL2, CSNK2A1, DRD4, ESR1, GSK3B, HDAC3, SRC, TOP2A, TP53, USP2 |
BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 2.106E-06 | 1.446E-04 | AKT1, BCL2, HIF1A, MMP9, PTGS2, PTPN1, SRC |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 2.130E-06 | 1.452E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1, STAT6 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 2.317E-06 | 1.562E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0009987; cellular process | GO:2000811; negative regulation of anoikis | 2.434E-06 | 1.631E-04 | BCL2, PIK3CA, PTK2, SRC |
BP | GO:0022610; biological adhesion | GO:0001952; regulation of cell-matrix adhesion | 3.624E-06 | 2.335E-04 | BCL2, GSK3B, KDR, PIK3CB, PIK3R1, PTK2, SRC |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 3.866E-06 | 2.476E-04 | AKT1, BCL2, HIF1A, LMNA, PTGS2, SRC, TP53 |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 4.613E-06 | 2.887E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0051179; localization | GO:0046326; positive regulation of glucose import | 6.782E-06 | 4.091E-04 | AKT1, INSR, MAPK14, NR1H4, PIK3R1 |
BP | GO:0032501; multicellular organismal process | GO:0043536; positive regulation of blood vessel endothelial cell migration | 7.614E-06 | 4.518E-04 | AKT1, HIF1A, KDR, MAPK14, PTGS2 |
BP | GO:0050896; response to stimulus | GO:0071498; cellular response to fluid shear stress | 7.813E-06 | 4.598E-04 | CA2, HDAC3, PTGS2, SRC |
MF | GO:0003824; catalytic activity | GO:0035005; 1-phosphatidylinositol-4-phosphate 3-kinase activity | 8.037E-06 | 4.658E-04 | PIK3CA, PIK3CB, PIK3CG |
BP | GO:0050896; response to stimulus | GO:0046626; regulation of insulin receptor signaling pathway | 1.304E-05 | 7.301E-04 | NR1H4, PIK3R1, PTPN1, PTPN2, SRC |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 8.415E-25 | 9.162E-21 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
MF | GO:0005488; binding | GO:0032052; bile acid binding | 1.911E-05 | 1.030E-03 | NR1H4, PLA2G1B, PYGL |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 1.911E-05 | 1.030E-03 | INSR, KDR, SYK |
MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 2.984E-05 | 1.540E-03 | AXL, IGF1R, INSR, PIK3R1 |
BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 3.349E-05 | 1.702E-03 | APP, CDK1, HDAC3, MAPK14, PIK3R1, PTGS2 |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 3.702E-05 | 1.849E-03 | AKR1B1, AKT1, ALOX5, APEX1, AURKB, BCL2, CAMK2B, CDC25B, CDK1, CSNK2A1, ESR1, ESR2, GMNN, GSK3B, HDAC3, HIF1A, HPGD, HTT, L3MBTL1, LMNA, MAPK14, NEK2, NEK6, NFKB1, NQO2, NR1H4, NUAK1, PIM1, PKN1, POLB, PTPN2, RECQL, SRC, STAT6, TOP2A, TP53, USP2 |
MF | GO:0005488; binding | GO:0034452; dynactin binding | 3.721E-05 | 1.854E-03 | GSK3B, HTT, MAPT |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 3.828E-05 | 1.869E-03 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 3.828E-05 | 1.869E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 3.828E-05 | 1.869E-03 | PTGS1, PTGS2 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 3.828E-05 | 1.869E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 3.828E-05 | 1.869E-03 | ALOX12, ALOX15 |
CC | GO:0044464; cell part | GO:0005739; mitochondrion | 4.343E-05 | 2.074E-03 | AKT1, APEX1, BCL2, CA5A, CA5B, CDK1, CYP1A1, CYP1B1, ESR2, GFER, GSK3B, HSD17B10, MAOA, MAPK14, MMP2, MPO, NFKB1, NOX4, PKM, SRC, TP53 |
BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 4.436E-05 | 2.094E-03 | AKT1, BCL2, DAPK1, HTT, LMNA, SRC |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 4.453E-05 | 2.094E-03 | CSNK2A1, HIF1A, KDR, MAPT |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 4.732E-05 | 2.221E-03 | BCL2, CA2, CA7, HTT, KDR, NPSR1, PLA2G1B, SRC |
BP | GO:0008152; metabolic process | GO:0010907; positive regulation of glucose metabolic process | 5.043E-05 | 2.336E-03 | AKT1, INSR, PTPN2, SRC |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 5.213E-05 | 2.398E-03 | HIF1A, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0009987; cellular process | GO:0007569; cell aging | 5.219E-05 | 2.398E-03 | BCL2, CDK1, MAPK14, NOX4, TP53 |
BP | GO:0008152; metabolic process | GO:0006081; cellular aldehyde metabolic process | 5.219E-05 | 2.398E-03 | AKR1B10, ALDH1A1, CYP1B1, GLO1, PGD |
MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 5.619E-05 | 2.555E-03 | MET, PIK3CA, PIK3CB, PIK3CG, PIK3R1 |
MF | GO:0005488; binding | GO:0042826; histone deacetylase binding | 5.789E-05 | 2.610E-03 | GMNN, HDAC3, HIF1A, PKN1, TOP2A, TP53 |
MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 5.789E-05 | 2.610E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, NQO2, XDH |
BP | GO:0009987; cellular process | GO:1900103; positive regulation of endoplasmic reticulum unfolded protein response | 6.391E-05 | 2.834E-03 | PIK3R1, PTPN1, PTPN2 |
BP | GO:0051179; localization | GO:0030100; regulation of endocytosis | 6.800E-05 | 3.004E-03 | ALOX15, APP, AXL, BCR, PIK3CB, PTPN1, SRC, SYK |
BP | GO:0050896; response to stimulus | GO:0048545; response to steroid hormone | 6.800E-05 | 3.004E-03 | ALPL, BCL2, CA2, CD38, FLT3, NPC1, PTGS2, SRC |
BP | GO:0065007; biological regulation | GO:0045124; regulation of bone resorption | 7.155E-05 | 3.141E-03 | CA2, CD38, SRC, SYK |
MF | GO:0005488; binding | GO:0002039; p53 binding | 7.461E-05 | 3.262E-03 | GSK3B, HIF1A, HTT, NUAK1, TP53 |
BP | GO:0032502; developmental process | GO:0060065; uterus development | 8.097E-05 | 3.484E-03 | CYP19A1, ESR1, SRC |
BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 8.214E-05 | 3.528E-03 | ALOX15, ESR1, GSK3B, MAPT, MET, MMP3, SRC, TP53 |
CC | GO:0016020; membrane | GO:0045121; membrane raft | 9.036E-05 | 3.850E-03 | APP, BACE1, INSR, KDR, NPC1, PTGS2, SLC6A2, SRC, STAT6 |
BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 9.123E-05 | 3.880E-03 | MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0009987; cellular process | GO:1903201; regulation of oxidative stress-induced cell death | 9.736E-05 | 4.109E-03 | AKT1, HIF1A, MET, MMP3, TP53 |
BP | GO:0050896; response to stimulus | GO:0071222; cellular response to lipopolysaccharide | 9.933E-05 | 4.167E-03 | AXL, BCR, MAPK14, NFKB1, NR1H4, SRC |
MF | GO:0003824; catalytic activity | GO:0016616; oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 9.933E-05 | 4.167E-03 | AKR1B1, AKR1B10, HPGD, HSD17B10, HSD17B2, PGD |
BP | GO:0022610; biological adhesion | GO:0033628; regulation of cell adhesion mediated by integrin | 1.089E-04 | 4.500E-03 | CYP1B1, PIK3CG, PTK2, SYK |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 1.106E-04 | 4.546E-03 | AXL, CDK1, CSNK2A1, FLT3, PKM |
BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 1.111E-04 | 4.547E-03 | ACHE, CD38, HIF1A, MAPK14, NR1H4, PLA2G1B, SRC, SYK |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.144E-04 | 4.562E-03 | CA2, CA7 |
BP | GO:0019740; nitrogen utilization | GO:0006808; regulation of nitrogen utilization | 1.144E-04 | 4.562E-03 | BCL2, NR1H4 |
BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 1.144E-04 | 4.562E-03 | GPBAR1, NR1H4 |
MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 1.144E-04 | 4.562E-03 | ALOX15, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.144E-04 | 4.562E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.144E-04 | 4.562E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.144E-04 | 4.562E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 1.144E-04 | 4.562E-03 | GPBAR1, NR1H4 |
BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 1.159E-04 | 4.614E-03 | AKT1, AURKB, CSNK2A1, L3MBTL1, MAPK14, NUAK1, TP53 |
BP | GO:0008152; metabolic process | GO:1901575; organic substance catabolic process | 1.192E-04 | 4.720E-03 | ACHE, AKR1B10, AKT1, ALDH1A1, APOBEC3G, AURKB, BACE1, CDK1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, GAA, GSK3B, HSD17B10, MAOA, PKM, PLA2G1B, PYGL, TP53, USP2, XDH |
MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 1.223E-04 | 4.806E-03 | ABCG2, ACHE, AKT1, APOBEC3G, BCL2, CAMK2B, FLT3, HPGD, MAPT, NFKB1, NQO2, PTGS2, PYGL, TOP2A, XDH |
BP | GO:0009987; cellular process | GO:0000226; microtubule cytoskeleton organization | 1.351E-04 | 5.273E-03 | AURKB, CDK1, HDAC3, HTT, LMNA, MAPT, NEK2, NEK6, PTK2 |
BP | GO:0009987; cellular process | GO:0060326; cell chemotaxis | 1.476E-04 | 5.660E-03 | ABCC1, CXCR1, PIK3CA, PIK3CB, PIK3CG, PLA2G1B, SYK |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 1.492E-04 | 5.665E-03 | CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 1.492E-04 | 5.665E-03 | AURKB, CDK1, PKN1 |
BP | GO:0009987; cellular process | GO:2000106; regulation of leukocyte apoptotic process | 1.585E-04 | 5.928E-03 | AURKB, AXL, HIF1A, PIK3CB, TP53 |
MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 1.587E-04 | 5.928E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
BP | GO:0032501; multicellular organismal process | GO:0051241; negative regulation of multicellular organismal process | 1.609E-04 | 5.964E-03 | ALOX12, APP, AXL, BCL2, BCR, CD38, GPR35, GSK3B, HIF1A, LMNA, NFKB1, NR1H4, PIK3CG, PIK3R1, PTGS2, PTK2, PTPN2, XDH |
BP | GO:0009987; cellular process | GO:0038096; Fc-gamma receptor signaling pathway involved in phagocytosis | 1.615E-04 | 5.964E-03 | PIK3CA, PIK3CB, PIK3R1, PTK2, SRC, SYK |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.632E-04 | 6.014E-03 | ABCC1, CA2, CA4, CA9, HPGD, SLCO1B1, SLCO1B3 |
BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 1.734E-04 | 6.344E-03 | AKT1, LMNA, MMP9, TP53 |
BP | GO:0008152; metabolic process | GO:0045862; positive regulation of proteolysis | 1.797E-04 | 6.533E-03 | AKT1, APP, CDK1, DAPK1, GSK3B, MAPK14, MAPT, PTK2, SRC, XDH |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 1.853E-04 | 6.703E-03 | BCL2, CAMK2B, CDK1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, HSD17B2, NOX4, PTGS1, PTGS2, RAB9A |
BP | Unclassified; | GO:0042993; positive regulation of transcription factor import into nucleus | 1.890E-04 | 6.801E-03 | APP, HDAC3, PIK3R1, PTGS2 |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 1.984E-04 | 7.047E-03 | HIF1A, MMP13, MMP2, MMP3, MMP9 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 1.984E-04 | 7.047E-03 | CYP3A4, ESR1, ESR2, NPC1, NR1H4 |
BP | GO:0002376; immune system process | GO:0002521; leukocyte differentiation | 2.278E-04 | 7.911E-03 | AXL, BCL2, FLT3, GLO1, MAPK14, MMP9, PIK3R1, PTPN2 |
BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 2.278E-04 | 7.911E-03 | PTPN1, PTPN2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.278E-04 | 7.911E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 2.278E-04 | 7.911E-03 | ESR1, ESR2 |
MF | GO:0005488; binding | GO:0051425; PTB domain binding | 2.278E-04 | 7.911E-03 | APP, INSR |
BP | GO:0050896; response to stimulus | GO:0071320; cellular response to cAMP | 2.616E-04 | 8.901E-03 | APEX1, APP, NOX4, PIK3CG |
MF | GO:0005215; transporter activity | GO:0005319; lipid transporter activity | 2.813E-04 | 9.481E-03 | ABCC1, ABCG2, HTT, NPC1, SLCO1B1, SLCO1B3 |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 2.866E-04 | 9.616E-03 | CYP1A1, POLB, TP53 |
MF | GO:0005488; binding | GO:0003682; chromatin binding | 2.919E-04 | 9.763E-03 | APEX1, CDK1, ESR1, GMNN, HDAC3, L3MBTL1, MPO, NFKB1, PKN1, TOP2A, TP53 |
BP | GO:0065007; biological regulation | GO:0043393; regulation of protein binding | 2.959E-04 | 9.867E-03 | APP, AURKB, BCL2, GSK3B, MET, MMP9, SRC |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.357E-17 | 3.322E-14 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.756E-16 | 1.416E-13 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 7.466E-24 | 1.404E-21 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 4.976E-15 | 4.678E-13 | CAMK2B; SRC; MMP2; PIK3R1; PIK3CB; MAPK14; HIF1A; ESR1; MMP9; PTK2; PIK3CG; IGF1R; PIK3CA; KDR; AKT1; TP53; MET |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 5.050E-13 | 3.165E-11 | GSK3B; PIK3CA; SRC; AKT1; PIK3CB; PIK3R1; MAPK14; ESR1; NFKB1; ESR2; PIK3CG |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.765E-12 | 1.082E-10 | GSK3B; FLT3; DAPK1; MMP2; PIK3CB; PIK3R1; PTGS2; HIF1A; MMP9; NFKB1; PIK3CG; PTK2; IGF1R; BCR; PIK3CA; BCL2; AKT1; MET; TP53 |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 2.878E-12 | 1.082E-10 | PIK3CA; SRC; KDR; AKT1; PIK3CB; PIK3R1; MAPK14; PTGS2; PTK2; PIK3CG |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.914E-11 | 5.140E-10 | GSK3B; SYK; CSNK2A1; PIK3R1; PIK3CB; MAPK14; NFKB1; PIK3CG; PIK3CA; BCL2; CDK1; AKT1; CD38; TP53 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 7.681E-12 | 2.407E-10 | PKM; PIK3CA; FLT3; AKT1; PIK3CB; PIK3R1; TP53; MET; HIF1A; PIK3CG |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.853E-11 | 6.704E-10 | CAMK2B; PIK3CA; INSR; BCL2; AKT1; PIK3R1; PIK3CB; HIF1A; NFKB1; PIK3CG; IGF1R |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 2.242E-10 | 3.011E-09 | GSK3B; SYK; INSR; PIK3R1; PIK3CB; PTK2; NFKB1; PIK3CG; IGF1R; PIK3CA; KDR; BCL2; AKT1; PKN1; TP53; MET |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 9.971E-11 | 2.083E-09 | PIK3CA; BCL2; AKT1; PIK3CB; PIK3R1; PTGS2; TP53; NFKB1; PTK2; PIK3CG |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.410E-10 | 2.205E-09 | GSK3B; PIK3CA; BCL2; AKT1; PIK3CB; PIK3R1; TP53; NFKB1; PIK3CG; IGF1R |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.155E-10 | 2.169E-09 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; CYP2C19; PTGS2; PTGS1 |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.269E-10 | 2.169E-09 | GSK3B; HDAC3; PIK3CA; SRC; AKT1; PIK3R1; PIK3CB; TP53; ESR1; HIF1A; PIK3CG |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.524E-10 | 2.205E-09 | CAMK2B; GSK3B; PIK3CA; BCL2; AKT1; PIK3R1; PIK3CB; MAPK14; TP53; NFKB1; PIK3CG |
hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 2.626E-10 | 3.291E-09 | GSK3B; SRC; PIK3R1; PIK3CB; PTK2; PIK3CG; MYLK; IGF1R; PIK3CA; KDR; BCL2; AKT1; MET |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 5.018E-10 | 5.241E-09 | PIK3CA; MMP2; PIM1; BCL2; AKT1; PIK3R1; PIK3CB; MAPK14; NFKB1; PIK3CG |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 4.110E-10 | 4.545E-09 | PIK3CA; SRC; MMP2; AKT1; PIK3R1; PIK3CB; ESR1; MMP9; ESR2; PIK3CG |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.261E-09 | 1.078E-08 | PIK3CA; SRC; BCL2; AKT1; STAT6; PIK3R1; PIK3CB; TP53; MMP9; NFKB1; PIK3CG |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.171E-09 | 1.048E-08 | PIK3CA; MMP3; AKT1; PIK3R1; PIK3CB; MAPK14; PTGS2; MMP9; NFKB1; PIK3CG |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.070E-09 | 1.006E-08 | PTPN1; GSK3B; PIK3CA; INSR; AKT1; PIK3R1; PIK3CB; PYGL; NFKB1; PIK3CG |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.399E-09 | 1.143E-08 | CYP2C9; APP; CYP2C8; MAOA; ALOX5; ALOX15; ALOX12; CYP2C19; PTGS2; PTGS1 |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 5.770E-10 | 5.709E-09 | ALOX5; INSR; HSD17B2; CYP1A1; CYP1B1; PTGS2; CYP19A1; IGF1R |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.661E-09 | 2.294E-08 | PLA2G1B; MAOA; ALOX15; AKR1B1; ALOX12; PYGL; PTGS2; CYP2C19; CYP3A4; CYP19A1; HSD17B10; PTGS1; ALOX5; HSD17B2; CD38; XDH; GAA; PGD; CYP2C9; CYP2C8; PKM; AKR1B10; CYP1A2; ALDH1A1; CYP1A1; ALPL; ALPI |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 3.898E-09 | 2.364E-08 | POLB; PKM; HDAC3; SYK; PIK3CA; SRC; CDK1; PIK3R1; PIK3CB; TP53; NFKB1; PIK3CG |
hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 3.240E-09 | 2.175E-08 | PIK3CA; SYK; SRC; AKT1; PIK3R1; PIK3CB; MAPK14; PIK3CG; MYLK; PTGS1 |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 2.577E-09 | 1.863E-08 | CAMK2B; GSK3B; PIK3CA; SRC; AKT1; PIK3CB; PIK3R1; PTK2; PIK3CG |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.756E-09 | 1.919E-08 | ABCC1; PIK3CA; BCL2; AKT1; PIK3R1; PIK3CB; MAPK14; TP53; NFKB1; PIK3CG |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.482E-09 | 1.161E-08 | PIK3CA; INSR; AKT1; PIK3CB; PIK3R1; PTGS2; PIK3CG; PTGS1 |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.715E-09 | 1.290E-08 | PIK3CA; FLT3; PIM1; AKT1; PIK3CB; PIK3R1; NFKB1; PIK3CG |
hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 7.482E-09 | 4.137E-08 | PIK3CA; CDK1; AKT1; PIK3R1; PIK3CB; MAPK14; PIK3CG; CDC25B; IGF1R |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 5.159E-09 | 2.939E-08 | PIK3CA; INSR; AKT1; PIK3CB; PIK3R1; TP53; NFKB1; PIK3CG; IGF1R |
hsa05162 | Measles_Homo sapiens_hsa05162 | 9.314E-09 | 5.003E-08 | GSK3B; PIK3CA; CSNK2A1; AKT1; RAB9A; PIK3R1; PIK3CB; TP53; NFKB1; PIK3CG |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 5.033E-09 | 2.939E-08 | CAMK2B; PIK3CA; AKT1; PIK3CB; PIK3R1; TP53; PIK3CG; IGF1R |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 3.422E-09 | 2.219E-08 | GSK3B; PIK3CA; BCL2; AKT1; PIK3CB; PIK3R1; TP53; PIK3CG |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.282E-10 | 3.856E-09 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 3.920E-08 | 1.755E-07 | PIK3CA; THPO; PIM1; BCL2; AKT1; STAT6; PIK3R1; PIK3CB; PTPN2; PIK3CG |
hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 5.901E-08 | 2.521E-07 | PIK3CA; SRC; INSR; KDR; AKT1; PIK3R1; PIK3CB; MAPK14; MET; PIK3CG; IGF1R |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.030E-08 | 5.377E-08 | PIK3CA; AKT1; PIK3CB; PIK3R1; TP53; MET; PIK3CG; IGF1R |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 3.846E-08 | 1.755E-07 | PIK3CA; ALOX5; BCL2; AKT1; PIK3R1; PIK3CB; MAPK14; NFKB1; PIK3CG |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.288E-08 | 6.372E-08 | BCR; PIK3CA; AKT1; PIK3CB; PIK3R1; TP53; NFKB1; PIK3CG |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.288E-08 | 6.372E-08 | GSK3B; PIK3CA; SYK; AKT1; PIK3CB; PIK3R1; NFKB1; PIK3CG |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.240E-07 | 4.960E-07 | PIK3CA; PLA2G1B; INSR; KDR; AKT1; PIK3R1; PIK3CB; MET; NFKB1; PIK3CG; IGF1R |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.086E-07 | 4.489E-07 | GSK3B; PIK3CA; AKT1; PIK3R1; PIK3CB; MAPK14; TP53; NFKB1; PIK3CG |
hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 1.331E-07 | 5.026E-07 | CAMK2B; PIK3CA; SRC; ALOX12; PIK3R1; PIK3CB; MAPK14; PIK3CG |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.340E-07 | 5.026E-07 | HPGD; FLT3; MMP3; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.687E-07 | 5.874E-07 | PIK3CA; LMNA; BCL2; AKT1; PIK3R1; PIK3CB; TP53; NFKB1; PIK3CG |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 3.265E-08 | 1.535E-07 | CYP2C9; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 1.914E-07 | 6.542E-07 | GSK3B; PIK3CA; CXCR1; SRC; AKT1; PIK3R1; PIK3CB; NFKB1; PTK2; PIK3CG |
hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.587E-07 | 5.736E-07 | PTPN1; GSK3B; PIK3CA; INSR; AKT1; PIK3R1; PIK3CB; PYGL; PIK3CG |
hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 3.501E-07 | 1.155E-06 | CAMK2B; ACHE; PIK3CA; BCL2; AKT1; PIK3R1; PIK3CB; PIK3CG |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 2.510E-08 | 1.210E-07 | GSK3B; PIK3CA; AKT1; PIK3CB; PIK3R1; TP53; PIK3CG |
hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 4.721E-07 | 1.479E-06 | CAMK2B; PIK3CA; SRC; CD38; PIK3R1; PIK3CB; PTGS2; PIK3CG; MYLK |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 2.115E-07 | 7.100E-07 | GSK3B; PIK3CA; AKT1; PIK3R1; PIK3CB; MAPK14; NFKB1; PIK3CG |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 4.266E-08 | 1.865E-07 | ALK; PIK3CA; AKT1; PIK3CB; PIK3R1; TP53; PIK3CG |
hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 1.098E-07 | 4.489E-07 | PIK3CA; INSR; AKT1; PIK3CB; PIK3R1; PIK3CG; IGF1R |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.780E-06 | 5.070E-06 | ABCC1; PIK3CA; PIM1; BCL2; CYP1B1; PTGS2; TP53; MMP9; MET; NFKB1; CDC25B |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.315E-06 | 3.924E-06 | PIK3CA; SYK; AKT1; PIK3R1; PIK3CB; MAPK14; NFKB1; PIK3CG |
hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 1.680E-07 | 5.874E-07 | PIK3CA; SYK; AKT1; PIK3CB; PIK3R1; MAPK14; PIK3CG |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.363E-07 | 5.026E-07 | PIK3CA; AKT1; PIK3CB; PIK3R1; TP53; NFKB1; PIK3CG |
hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 1.392E-06 | 4.090E-06 | PIK3CA; INSR; AKT1; PIK3R1; PIK3CB; MAPK14; PIK3CG; IGF1R |
hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 5.601E-07 | 1.726E-06 | PIK3CA; MMP2; PIK3R1; PIK3CB; MAPK14; MMP9; PTK2; PIK3CG |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 2.531E-06 | 6.935E-06 | PIK3CA; SYK; CXCR1; INSR; AKT1; PIK3R1; PIK3CB; PIK3CG |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 2.279E-06 | 6.395E-06 | GSK3B; PIK3CA; AKT1; PIK3R1; PIK3CB; MAPK14; PIK3CG; IGF1R |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.363E-07 | 5.026E-07 | PIK3CA; AKT1; PIK3CB; PIK3R1; MET; HIF1A; PIK3CG |
hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 3.106E-06 | 8.224E-06 | CAMK2B; PIK3CA; BCL2; AKT1; PIK3R1; PIK3CB; MAPK14; PIK3CG |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 3.607E-06 | 9.081E-06 | GSK3B; PIK3CA; INSR; AKT1; PIK3R1; PIK3CB; NFKB1; PIK3CG |
hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 4.359E-07 | 1.389E-06 | PIK3CA; SRC; PIK3CB; PIK3R1; MET; PTK2; PIK3CG |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 3.082E-06 | 8.224E-06 | PIK3CA; AKT1; PIK3R1; PIK3CB; MAPK14; NFKB1; PIK3CG |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 3.501E-06 | 9.016E-06 | PIK3CA; AKT1; PIK3R1; PIK3CB; MAPK14; NFKB1; PIK3CG |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 2.589E-05 | 5.864E-05 | POLB; GSK3B; PIK3CA; AKT1; PIK3R1; PIK3CB; TP53; NFKB1; PIK3CG |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.069E-05 | 2.482E-05 | GSK3B; PIK3CA; AKT1; PIK3R1; PIK3CB; MAPK14; NFKB1; PIK3CG |
hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 9.894E-06 | 2.325E-05 | PIK3CA; INSR; AKT1; PIK3R1; PIK3CB; PIK3CG; IGF1R |
hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 6.729E-05 | 1.454E-04 | PIK3CA; INSR; AKT1; PIK3R1; PIK3CB; PIK3CG; MYLK |
hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 3.117E-04 | 6.233E-04 | PIK3CA; SRC; PIK3R1; PIK3CB; PTK2; PIK3CG; MYLK |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.004E-04 | 2.098E-04 | CAMK2B; SYK; SRC; BCL2; AKT1; MAPK14; NFKB1 |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 4.416E-03 | 7.982E-03 | AKT1; MAPT; MAPK14; TP53; NFKB1; CDC25B |
hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 2.005E-02 | 3.202E-02 | CXCR1; SRC; KDR; MET; IGF1R |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 2.002E-04 | 4.091E-04 | CAMK2B; PIK3CA; AKT1; PIK3R1; PIK3CB; NFKB1; PIK3CG |
hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 2.188E-02 | 3.457E-02 | CXCR1; THPO; FLT3; KDR; MET |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 3.454E-03 | 6.367E-03 | BACE1; APP; GSK3B; MAPT; HSD17B10 |
hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 1.333E-03 | 2.583E-03 | PIK3CA; SYK; PIK3R1; PIK3CB; PIK3CG |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 2.541E-02 | 3.948E-02 | CSNK2A1; CDK1; TP53; NFKB1 |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.061E-02 | 1.796E-02 | CAMK2B; GSK3B; CSNK2A1; TP53 |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 6.652E-03 | 1.191E-02 | GSK3B; CDK1; TP53; CDC25B |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 3.277E-05 | 7.248E-05 | PIK3CA; AKT1; PIK3R1; PIK3CB; HIF1A; PIK3CG |
hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 1.283E-04 | 2.652E-04 | CAMK2B; GSK3B; MAOA; AKT1; MAPK14; DRD4 |
hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 2.049E-05 | 4.698E-05 | PIK3CA; SYK; AKT1; PIK3CB; PIK3R1; PIK3CG |
hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 3.097E-05 | 6.932E-05 | PIK3CA; PIK3R1; PIK3CB; NFKB1; PTK2; PIK3CG |
hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 3.216E-03 | 5.986E-03 | CAMK2B; PKM; AKT1; PYGL |
hsa04070 | Phosphatidylinositol signaling system_Homo sapiens_hsa04070 | 2.885E-03 | 5.478E-03 | PIK3CA; PIK3R1; PIK3CB; PIK3CG |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 2.204E-03 | 4.228E-03 | CAMK2B; SRC; MMP2; MAPK14 |
hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 2.010E-02 | 3.202E-02 | CA2; PLA2G1B; CD38 |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.581E-06 | 4.573E-06 | PIK3CA; AKT1; PIK3CB; PIK3R1; HIF1A; PIK3CG |
hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 1.597E-02 | 2.634E-02 | THPO; FLT3; CD38 |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.503E-02 | 2.522E-02 | PKN1; MAPK14; NFKB1 |
hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 2.439E-04 | 4.931E-04 | SYK; CSNK2A1; BCL2; PTGS2; NFKB1 |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 9.657E-03 | 1.666E-02 | MAPK14; PTGS2; NFKB1 |
hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 1.002E-02 | 1.713E-02 | CAMK2B; CA2; MYLK |
hsa00562 | Inositol phosphate metabolism_Homo sapiens_hsa00562 | 8.952E-03 | 1.558E-02 | PIK3CA; PIK3CB; PIK3CG |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.545E-06 | 6.935E-06 | CYP2C9; CYP2C8; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 5.464E-06 | 1.317E-05 | PTPN1; CSNK2A1; SRC; INSR; MET; IGF1R |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.291E-06 | 3.914E-06 | CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.286E-06 | 1.060E-05 | SLCO1B1; CA2; SLCO1B3; NR1H4; CYP3A4; ABCG2 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.623E-06 | 9.081E-06 | CYP2C9; CYP2C8; MAOA; CYP1A2; CYP3A4; CYP2C19 |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 7.021E-03 | 1.245E-02 | SRC; MAPK14; NFKB1 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 7.755E-05 | 1.657E-04 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 4.109E-07 | 1.332E-06 | PKM; PIK3CA; INSR; PIK3CB; PIK3R1; PIK3CG |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 5.512E-05 | 1.205E-04 | CXCR1; SRC; MAPK14; MET; NFKB1 |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 3.112E-02 | 4.757E-02 | CYP3A4; XDH |
hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 3.557E-03 | 6.492E-03 | BCL2; MAPK14; TP53 |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 2.867E-02 | 4.417E-02 | ABCC1; ABCG2 |
hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 2.400E-02 | 3.761E-02 | PKM; GLO1 |
hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 1.969E-02 | 3.191E-02 | AKR1B10; AKR1B1 |
hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 7.211E-06 | 1.716E-05 | PIK3CA; AKT1; PIK3CB; PIK3R1; PIK3CG |
hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 1.575E-02 | 2.620E-02 | AKR1B10; AKR1B1 |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 1.670E-02 | 2.730E-02 | POLB; APEX1 |
hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 3.497E-06 | 9.016E-06 | PIK3CA; INSR; PIK3CB; PIK3R1; PIK3CG |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 4.509E-06 | 1.101E-05 | DAPK1; SRC; MMP2; MMP9; TP53 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 7.598E-04 | 1.488E-03 | AKR1B10; GAA; AKR1B1 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 9.532E-05 | 2.013E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 8.318E-03 | 1.462E-02 | CA2; CA4 |
hsa00790 | Folate biosynthesis_Homo sapiens_hsa00790 | 3.099E-03 | 5.826E-03 | ALPL; ALPI |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 3.528E-04 | 6.982E-04 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; PTGS1; ESR1 |
I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | MAPK14 |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK; BCL2 |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; PTGS2; PTGS2; MAPK14 |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
NA: NA | Miosis during ocular surgery | NA | PTGS1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | SLC6A2 |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ALOX5; ALOX5; SYK; SYK; PTGS2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; ESR1; ESR1 |
C00-D49: Neoplasms | Multiple myeloma | C90 | SRC; IGF1R; CD38; BCL2 |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | SLC6A2; SLC6A2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PIK3CA; PTK2; TP53 |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; MYLK; CA2 |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; PKM; SYK; PIK3CA; PIK3CG; FLT3; CA9; MMP2; SRC; IGF1R; AURKB; HIF1A; MMP9; PTK2; TP53; PIK3CB; KDR; KDR; KDR; TOP2A |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3; MAPK14; BCL2 |
NA: NA | Colour dead tissues | NA | PTPN1 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; PTGS1; IGF1R; MMP9; TP53; KDR |
NA: NA | Geographic retinal atrophy | NA | APP |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; FLT3; MMP2; PTGS2; KDR |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; MAPK14 |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2 |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK; PIK3CB |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; PIK3CG; PIK3CG |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
C00-D49: Neoplasms | Colon cancer | C50 | ALPL; FLT3 |
C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; KDR; KDR; KDR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; PLA2G1B; ALOX5; SYK; MMP3; CAMK2B; PTGS2; PTGS2; PTGS2; PTGS2; MAPK14 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; SYK |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; INSR; MAPT; ACHE; ACHE; ACHE; PTGS2; GSK3B; APP |
A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3; BCL2; ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | MAPK14; MAPK14 |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PIK3CG; MMP3 |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
NA: NA | Acute respiratory distress syndrome | NA | MAPK14 |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | SLC6A2 |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; SLC6A2; SLC6A2; SLC6A2; SLC6A2 |
NA: NA | GIST | NA | FLT3 |
C00-D49: Neoplasms | Glioma | C71 | PIK3CG; KDR; APP |
A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; CAMK2B; ACHE; SLC6A2; CYP3A4 |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
NA: NA | Angioedema | NA | PIK3CG |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13; SYK; PIK3CG; PTGS1; PTGS2; MAPK14 |
NA: NA | Inflammatory diseases | NA | MAPK14 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK; PIK3CG; PIK3CG |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; PTGS2; IGF1R; IGF1R; AXL; KDR |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; SLC6A2 |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | PIK3CG; CYP2C9 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
C00-D49: Neoplasms | Neuroblastoma | C74.1, C74.9, C75.4, C75.5, D35.0, D35.5, D35.6, D44.6, D44.7 | SLC6A2 |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS1; PTGS2; PTGS2 |
C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1; PIK3CG |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; AURKB; TP53; TP53 |
J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | MAPK14 |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | PIK3CG; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1 |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; SLC6A2 |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TP53; KDR; KDR |
A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; SRC |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
NA: NA | Edema | NA | CA2 |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2 |
C00-D49: Neoplasms | Endometrial cancer | C54.1 | PIK3CG; PIK3CG |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD4 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ALOX5; PIK3CG; PTGS2; PTGS2; MAPK14 |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2 |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; SLC6A2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
NA: NA | Enthesopathy | NA | PIK3CG |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
NA: NA | Gonorrheal vaginitis | NA | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; PTGS2; XDH |
C00-D49: Neoplasms | Melanoma | C43 | KDR; KDR |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; ESR1; ESR1 |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; MMP9 |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; ESR1 |
C00-D49: Neoplasms | Breast cancer | C50 | INSR; CYP19A1; PIK3CG; FLT3; FLT3; CA9; NQO2; IGF1R; CDK1; BCL2; ESR1; ESR1; KDR; KDR; KDR |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | SLC6A2 |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; PTGS1 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; ESR1 |
C00-D49: Neoplasms | Neuroendocrine cancer | C7A | SLC6A2 |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | INSR; PKM; MMP13; ACHE; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; IGF1R; CDK1; SLC6A2; ESR1 |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
NA: NA | Upper abdominal bloating | NA | ACHE |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | PIK3CG; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; INSR; PTPN1; GSK3B |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | MAPK14 |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR; PTPN1; PTPN1; PIK3CG; PIK3CG; PTGS2; NFKB1; GPBAR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
NA: NA | Joint and muscular pain | NA | PTGS2 |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | SLC6A2 |
C00-D49: Neoplasms | Cancer | C00-C96 | AKT1; MET; CSNK2A1; SYK; PIK3CA; PIK3CG; CA1; FLT3; FLT3; CA9; MMP2; NQO2; ACHE; PTGS2; SRC; IGF1R; CD38; GSK3B; HIF1A; CDK1; MAPK14; MMP9; NFKB1; PIM1; CDC25B; PTK2; BCL2; BCL2; TP53; PIK3CB; ESR1; ESR1; KDR; APP |
H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
C00-D49: Neoplasms | Diffuse large B-cell lymphoma | C83.3 | PIK3CG |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
C00-D49: Neoplasms | Prostate cancer | C61 | PIK3CG; FLT3; BCL2; ESR1 |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR; SYK; ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2; MAPK14 |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; ESR1; APP |
NA: NA | Menopausal disorder | NA | ESR1 |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; INSR; PIK3CG; PIK3CG; CA9; HIF1A; BCL2 |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; SRC; CD38; AURKB; TP53 |
C00-D49: Neoplasms | AML | NA | FLT3; KDR |
C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
NA: NA | Postmenopausal disorder | NA | ESR1 |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
C00-D49: Neoplasms | CLL | NA | FLT3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |